(Q24240511)

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

Ramosetron for the prevention of cisplatin-induced acute emesis: a prospective randomized comparison with granisetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

A double-blind, crossover, randomized comparison of granisetron and ramosetron for the prevention of acute and delayed cisplatin-induced emesis in patients with gastrointestinal cancer: is patient preference a better primary endpoint?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and Vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

Pharmacokinetics of ondansetron in patients with hepatic insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

Delayed emesis following anticancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

The control of chemotherapy-induced emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

A CONTROLLED CLINICAL EVALUATION OF ANTIEMETIC DRUGS

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

7 January 2021

Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

7 January 2021

Antiemetic guidelines: creating a more practical treatment approach

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

7 January 2021

Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

7 January 2021

Randomised double blind crossover study comparing ondansetron, granisetron and tropisetron. A cost-benefit analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

7 January 2021

Blockade of neuronal tryptamine receptors by metoclopramide

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

7 January 2021

Profiles of emetic action of cisplatin in the ferret: a potential model of acute and delayed emesis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

7 January 2021

ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

7 January 2021

A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

7 January 2021

Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

7 January 2021

Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Em

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

7 January 2021

Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

7 January 2021

Neuropharmacology of Chemotherapy-induced Emesis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006272.PUB2

7 January 2021

Controlling Emesis in Patients Receiving Cancer Chemotherapy

1 reference

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD006272.PUB2

Intravenous metoclopramide. An effective antiemetic in cancer chemotherapy

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD006272.PUB2

ET-Kyoto solution plus dibutyryl cyclic adenosine monophosphate is superior to University of Wisconsin solution in rat liver preservation

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD006272.PUB2

Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD006272.PUB2

Receptors of the enteric nervous system: potential targets for drug therapy.

9 February 2024

1 reference

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD006272.PUB2